Stoke Therapeutics, Inc. STOK Accrued And Other Current Liabilities
Accrued And Other Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept stok:AccruedAndOtherCurrentLiabilities.
The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Stoke Therapeutics, Inc.'s accrued and other current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Stoke Therapeutics, Inc.'s accrued and other current liabilities?
- Stoke Therapeutics, Inc. (STOK) reported accrued and other current liabilities of $23.9M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s accrued and other current liabilities changed year-over-year?
- Stoke Therapeutics, Inc.'s accrued and other current liabilities decreased by 1.8% year-over-year, from $24.34M to $23.9M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s accrued and other current liabilities?
- Over 5 years (2020 to 2025), Stoke Therapeutics, Inc.'s accrued and other current liabilities has grown at a 32.8% compound annual growth rate (CAGR), from $9.93M to $41.04M.
- What does accrued and other current liabilities mean?
- This category aggregates short-term obligations that are owed to third parties but have not yet been formally invoiced or settled as of the reporting date. It typically includes items such as accrued compensation, professional fees, and other operational expenses incurred in the normal course of business that are due within one year. Tracking these liabilities is essential for assessing the company's near-term cash outflow requirements and operational expense management.